NCT04486937View on ClinicalTrials.gov

SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 30, 2020

Primary Completion Date

December 30, 2021

Study Completion Date

June 30, 2022

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

S410914 tablet

S410914 tablet

Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY